

## DAFTAR PUSTAKA

- Abd El Atti, R. M., Abou Gabal, H. H., Osman, W. M., and Saad, A. S., 2013. *Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors. Diagnostic Pathology*, 8(1), p. 1.
- Adams, H., Chaichana, K. L., Avendaño, J., Liu, B., Raza, S. M., & Quiñones-Hinojosa, A. 2013. *Adult Cerebellar Glioblastoma: Understanding Survival and Prognostic Factors Using a Population-Based Database from 1973 to 2009. World Neurosurgery*, 80(6), e237–e243.
- Ambroise, M. M., Khosla, C., Ghosh, M., Mallikarjuna, V. S., Annapurneswari, S., 2011. *Practical value of MIB-1 index in predicting behavior of astrocytomas. Indian J Pathol Microbiol*, 20(54); 520-5.
- Arshad, H., Ahmad, Z., Hasan., S. H., 2010. *Gliomas: Correlation of histologic grade, Ki67 and p53 expression with patient survival. Asian Pacific Journal of Cancer Prevention*, 11(6), pp. 1637–1640.
- Bansal, K., Liang, M. L., and Rutka, J. T., 2006. *Molecular biology of human gliomas. Technol Cancer Res Treat*. 5(3):185-94.
- Barthel, F. P., Wesseling, P., Verhaak, R. G. W. 2018. *Reconstructing The Molecular Life History of Gliomas. Acta Neuropathol*, 135(5):649-670.
- Blionas, A., Giakoumettis, D., Klonou, A., et al. 2018. *Paediatric gliomas: diagnosis, molecular biology and management. Annals of Translational Medicine*, 6(12), pp. 251–251.
- Bredel, M., Piribauer, M., Marosi, C., et al. 2002. *High expression of DNA topoisomerase IIα and Ki-67 antigen is associated with prolonged survival in glioblastoma patients. European Journal of Cancer*, 38(10), pp. 1343–1347.
- Chen, W.J., He, D.S., Tang, R.X., Ren, F.H., Chen, G, et al. 2015. *Ki-67 is a valuable prognostic factor in gliomas: Evidence from a systematic review and meta-analysis. Asian Pacific Journal of Cancer Prevention*, 16(2), pp. 411–420.

- Chesnelong, C., Chaumeil, M. M., Blough, M. D., Al-Najjar, M., Stechishin, O. D., Chan, J. A. 2014. *Lactate Dehydrogenase A Silencing in IDH Mutant Gliomas*. [Neuro Oncol.](#) 16(5):686-95.
- Cohen, A.L., Holmen, S.L., Colman, H., 2013. *IDH1 and IDH2 Mutations in Gliomas*. *Current Neurology and Neuroscience Reports*, 13(5).
- Dahlrot, R. H. 2014. *The prognostic value of clinical factors and cancer stem cell-related markers in gliomas*. *Danish Medical Journal*, 61(10), pp. 1–27.
- Deng, L., Xiong, P., Yunhui, L., Bu, X., Qian, S., Zhong, W., et al. 2018. *Association between IDH1/2 mutations and brain glioma grade*. *Oncology Letters* 16: 5405-5409.
- Fisher, B. J., Naumova, E., Leighton, C. C., Naumov, G. N., Kerkviet, N., Fortin, D., et al. 2002. *Ki-67: A prognostic factor for low-grade glioma?*. *International Journal of Radiation Oncology Biology Physics*, 52(4), pp. 996–1001.
- Gupta, A., Dwivedi, T., 2017. *A Simplified Overview of World Health Organization Classification Update of Central Nervous System Tumors 2016*. *J Neurosci Rural Pract*, 8(4): 629–641.
- Gzell, C., Wheeler, H., Huang, D., Gaur, P., Chen, J., Kastelan, M., & Back, M. 2016. *Proliferation Index Predicts Survival after Second Craniotomy within 6 Months of Adjuvant Radiotherapy for High-grade Glioma*. *Clinical Oncology*, 28(3), 215–222.
- Habberstand, A. H., Gulati, S., Torp, S. H. 2011. *Evaluation of the proliferation markers Ki-67/MIB-1, mitotin, survivin, pHH3, and DNA topoisomerase IIα in human anaplastic astrocytomas - an immunohistochemical study*. *Diagnostic Pathology*, 6(1), pp. 2–9.
- Hayat, M. A. 2010 *Tumors of the Central Nervous System. Gliomas: Glioblastoma (Part1)*, *Neuromethods*, p. 3.
- Hsu, C. Y., Ho, D. M. T., Yang, C. F., Chiang, H., 2003. *Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods*. *Modern Pathology*, 16(9), pp. 951–957.

- Jang, M. H., Kim, H. J., Chung, Y. R., Lee, Y. and Park, S. Y., 2017. A comparison of Ki-67 counting methods in luminal breast cancer: the average method vs. the hot spot method. *PloS one*, 12(2), p.e0172031.
- Jiang, Y., Uhrbom, L., On The Origin of Glioma. [Ups J Med Sci](#). 2012 May;117(2):113-21.
- Johannessen, A. L., & Torp, S. H. 2006. *The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathology & Oncology Research*, 12(3), 143–147.
- Kanyilmaz, G., Önder, H., Aktan, M., Mehmet, K.O.Ç., Hüseyin, B.O.R.A., Karahacıoğlu, E., et al. 2018. *Prognostic importance of Ki-67 labeling index in grade II glial tumors. Turk Onkoloji Dergisi*, 33(2), pp. 48–53.
- Korshunov, A., Sycheva, R., and Golanov, A. 2005. *The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years. Cancer*, 104(4), pp. 825–832.
- Krishnan, S. S., Muthiah, S., Rao, S., Salem, S. S., Madabhushi, V. C., Mahadevan, A., 2019. *Collaborative Tele-Neuropsychiatry Consultation Services for Patients in Central Prisons. Journal of Neurosciences in Rural Practice*, 79(1), pp. 68–72.
- Leece, R., Xu, J., Ostrom, Q. T., Chen, Y., Kruchko, C., Barnholtz-Sloan, J. S., 2017. *Global incidence of malignant brain and other central nervous system tumors by histology, 2003-2007. Neuro-Oncology*, 19(11), pp. 1553–1564.
- Leung, S. C. Y., Nielsen, T. O., Zabaglo, L., Arun, I., Badve, S.S., Bane, A.L., et al. 2016. *Analytical validation of a standardized scoring protocol for Ki67: Phase 3 of an international multicenter collaboration. npj Breast Cancer*, 2(1), pp. 1–9.
- Li, L. T., Jiang, G., Chen, Q., and Zheng, J. N., 2015. *Predic Ki67 is a promising molecular target in the diagnosis of cancer (Review). Molecular Medicine Reports*, 11(3), pp. 1566–1572.
- Louis, D. N., Ohgaki, H., Wiestler, O. D., and Cavenee, W. K., 2016. *World Health Organization Classification of Tumours of the Central Nervous*

- System*. 4th edn. *Diffuse astrocytic and oligodendroglial tumours, other astrocytic tumours Pilocytic, Ependymal tumours, and other gliomas*. International Agency for Research on Cancer (IARC), Lyon, France, 10-122.
- Menon, S. S., Guruvayoorappan, C., Sakthivel, K. M., and Rasmi, R. R., 2019. *Ki-67 protein as a tumour proliferation marker*. *Clinica Chimica Acta*. Elsevier, 491 (19), pp. 39–45.
- Miller, J. J., Shih, H. A., Andronesi, O. C., & Cahill, D. P., 2017. *Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications*. *Cancer*, 123(23), 4535–4546.
- Nielsen, L. A. G., Bangsø, J. A., Lindahl, K. H., Dahlrot, R. H., Hjekmborg, J. V. B., Hansen, S., *et al.* 2018. Evaluation of the proliferation marker Ki-67 in gliomas: Interobserver variability and digital quantification. *Diagnostic Pathology*, 13(1), pp. 1–8.
- Ohgaki, H., & Kleihues, P. 2007. *Genetic Pathways to Primary and Secondary Glioblastoma*. *The American Journal of Pathology*, 170(5), 1445–1453.
- Ohgaki, H., & Kleihues, P. 2012. *The Definition of Primary and Secondary Glioblastoma*. *Clinical Cancer Research*, 19(4), 764–772.
- Ostrom, Q. T., Rubin, J. B., Lathia, J. D., Berens, M.E., and Barnholtz-Sloan, J.S. 2018. *Females have the survival advantage in glioblastoma*. *Neuro-Oncology*, 20(4), pp. 576–577.
- Ostrom, Q. T., Kinnnersley, B., Wensch, M. R., Eckel-Passow, J. E., *et al.* 2018. *Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21*. *Scientific Reports*, 8(1), pp. 1–15.
- Perry, A., Brat, D. J., 2018. *Practical Surgical Neuropathology: A Diagnostic Approach, Second Edition*. pp. 91-169, Elsevier, Inc.
- Pignatti, B. F., Bent, M. V. D., Curran, D., Debruyne, C., *et al.* 2009. *Cerebral Low-Grade Glioma*. *Society*, 20(8), pp. 2076–2084.
- Pollack, I. F., Hamilton, R. L., Burnham, J., Holmes, E. J., Finkelstein, S. D., Sposto, R., *et al.*, 2002. *Impact of Proliferation Index on Outcome in*

- Childhood Malignant Gliomas: Results in a Multi-institutional Cohort.* Neurosurgery. 50(6); 1238-1245.
- Rasmussen, B. K., Hansen, S., Laursen, R. J., Kosteljanetz, M., Schultz, H., Nørgård, B. M., *et al.* 2017. *Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I–IV in the the Danish Neuro-Oncology Registry.* *Journal of Neuro-Oncology*, 135(3), 571–579.
- Reavey-Cantwell J.F., Haroun R. I., Zahurak M., & Clatterbuck R. E., *et al.*, 2001. *The prognostic value of tumor markers in patients with glioblastoma multiforme: Analysis of 32 patients and review of the literature.* *Journal of Neuro-Oncology*, 55(3), pp. 195–204.
- Sales Gil, R., Vagnarelli, P., 2018. *Ki-67: More Hidden behind a 'Classic Proliferation Marker'.* [\*Trends Biochem Sci\*](#), 43(10):747-748.
- Seo, S. H., Kim, K. H., Oh, S. H., Choi, Y., Ahn, K. J., Lee, J. Y., *et al.* 2019. *Ki-67 Labeling Index as A Prognostic Marker in Advanced Stomach Cancer.* *Ann Surg Treat Res*, 96(1): 27–33.
- Skjulsvik, A. J., Mørk, J.N., Torp, M.O., and Torp, S.H. 2014. *Ki-67/MIB-1 Immunostaining In A Cohort of Human Gliomas.* *International journal of clinical and experimental pathology*, 7(12), p.8905.
- Stark, A.M., Van De Bergh, J., Hedderich, J., Mehdorn, H. M., and Nabavi, A., 2012. *Glioblastoma: Clinical characteristics, prognostic factors and survival in 492 patients.* *Clinical Neurology and Neurosurgery*, 114(7), pp. 840–845.
- Sturm, D., Pfister, S. M., & Jones, D. T. W. 2017. *Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management.* *Journal of Clinical Oncology*, 35(21), 2370–2377.
- Strauss, I., Jonas-Kimchi, T., Bokstein, F., *et al.*, 2013. *Gliomas of the posterior fossa in adults.* *Journal of Neuro-Oncology*, 115(3), pp. 401–409.
- Sun, X., & Kaufman, P. D., 2018. *Ki-67: More Than A Proliferation Marker.* [\*Chromosoma\*](#), 127(2):175-186.

- Thakkar, J. P., Dolecek, T. A., Horbinski, C., Ostrom, Q. T., Lightner, D. D., Barnholtz-Sloan J. S., et al., 2014. *Epidemiologic and Molecular Prognostic Review of Glioblastoma. Cancer Epidemiol Biomarkers Prev.* 23(10): 1985–1996
- Tavares, C. B., Gomes Braga, F. D. C., Sheyla, A., Sousa, E. B., and Brito, J.N.P.O., 2018. *Expression of Ki-67 in Low-Grade and High-Grade Astrocytomas. Jbnc - Jornal Brasileiro De Neurocirurgia*, 27(3), pp. 225-230.
- Theresia, E., Malueka, R. G., Pranacipta, S., Kameswari, B., Dananjoyo, K., Asmedi, A., et al., 2020. Association between Ki-67 Labeling index and Histopathological Grading of Glioma in Indonesian Population. *Asian Pac J Cancer Prev.* 1;21(4):1063-1068.
- Tian, M., Ma, W., Chen, Y., et al., 2018. *Impact of gender on the survival of patients with glioblastoma, Bioscience Reports*, 38(6), pp. 1–9.
- Uematsu, M., Ohsawa, I., Aokage, T., Nishimaki, K., Matsumoto, K., Takahashi, H., et al., 2005. *Prognostic Significance of The Immunohistochemical Index Of Survivin In Glioma: A Comparative Study with The MIB-1 Index*, 72(3):231-8.
- Walid, M., 2008. *Prognostic Factors for Long-Term Survival after Glioblastoma. The Permanente Journal*, 12(4), pp. 45–48.
- Wang, J., Hu, G. and Quan, X., 2019. *Analysis of the factors affecting the prognosis of glioma patients. Open Medicine (Poland)*, 14(1), pp. 331–335.
- Wesseling, P., and Capper, D., 2018. *WHO 2016 Classification of Gliomas. Neuropathology and applied neurobiology*, 44(2), pp.139-150.
- Wong, E., Nahar, N., Hau, E., Varikatt, W., Gebiski, V., Ng, T., et al. 2018. *Cut-Point For Ki-67 Proliferation Index As A Prognostic Marker for Glioblastoma. Asia-Pacific Journal of Clinical Oncology*.
- Zeng, A., Hu, Q., Liu, Y., Wang, Z., Cui, X., Li, R., Yan, W., You, Y. 2015. *IDH1/2 Mutation Status Combined with Ki-67 Labeling Index Defines Distinct Prognostic Groups in Glioma. Oncotarget.* 6(30):30232-8.